ERYTECH Pharma S.A.
Develops red blood cell-based therapies for cancer and orphan diseases.
ERYP | PA
Overview
Corporate Details
- ISIN(s):
- FR0010417360 (+2 more)
- LEI:
- 969500U8ZZCODU8A9374
- Country:
- France
- Address:
- 60 AVENUE ROCKEFELLER, 69008 LYON
- Website:
- https://phaxiam.com/
- Sector:
- Manufacturing
Description
ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on its proprietary ERYCAPS platform, which encapsulates drug substances inside red blood cells. This technology is designed to improve the efficacy and safety of treatments by prolonging the drug's circulation time and reducing side effects. The company's primary focus is on developing treatments for severe forms of cancer and orphan diseases. Its lead product candidate, eryaspase, encapsulates the enzyme L-asparaginase to starve cancer cells of essential nutrients, targeting indications such as acute lymphoblastic leukemia and pancreatic cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-11-18 18:00 |
PHAXIAM a présenté son test IVD Phagogramme et l’actualisation du suivi de sens…
|
French | 240.6 KB | ||
| 2024-11-18 18:00 |
PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility track…
|
English | 255.8 KB | ||
| 2024-11-13 17:45 |
PHAXIAM Reports Third-Quarter 2024 Financial Information
|
English | 215.3 KB | ||
| 2024-11-13 17:45 |
PHAXIAM publie l’information financière du troisième trimestre 2024
|
French | 205.6 KB | ||
| 2024-11-08 18:00 |
Monthly information related to total number of voting rights and shares composi…
|
English | 159.4 KB | ||
| 2024-11-08 18:00 |
Information mensuelle relative au nombre total de droits de vote et d’actions c…
|
French | 175.8 KB | ||
| 2024-11-04 18:00 |
PHAXIAM Therapeutics obtient l’autorisation de la FDA américaine pour lancer l’…
|
French | 242.6 KB | ||
| 2024-11-04 18:00 |
PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study i…
|
English | 212.8 KB | ||
| 2024-10-10 18:00 |
Monthly information related to total number of voting rights and shares composi…
|
English | 159.2 KB | ||
| 2024-10-10 18:00 |
Information mensuelle relative au nombre total de droits de vote et d’actions c…
|
French | 175.5 KB | ||
| 2024-10-09 18:00 |
PHAXIAM Therapeutics annonce la validation d’une nouvelle étude de phase 2, PH…
|
French | 248.4 KB | ||
| 2024-10-09 18:00 |
PHAXIAM Therapeutics announces the validation of a new investigator-initiated p…
|
English | 220.2 KB | ||
| 2024-09-25 17:45 |
PHAXIAM fait le point sur ses activités et publie ses résultats financiers du p…
|
French | 303.2 KB | ||
| 2024-09-25 17:45 |
PHAXIAM Provides Business and Financial Update For the First Half of 2024
|
English | 279.7 KB | ||
| 2024-09-25 17:45 |
PHAXIAM : RAPPORT FINANCIER SEMESTRIEL
|
French | 786.5 KB |
Automate Your Workflow. Get a real-time feed of all ERYTECH Pharma S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ERYTECH Pharma S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ERYTECH Pharma S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-06-23 | N/A | Other | Other | 3,697,533 | 2,255,495.13 EUR |
| 2023-06-23 | N/A | Other | Other | 71,839 | 43,821.79 EUR |
| 2023-06-23 | N/A | Other | Other | 54,862 | 33,465.82 EUR |
Peer Companies
